With the prevalence of atrial fibrillation (AF) on the rise, novel devices and medical therapies have entered the market to help providers manage this challenging patient population. One such device is the Watchman, an interventional therapy that aims to mitigate stroke risk in AF patients.
While the Watchman has generated considerable enthusiasm among some CV program leaders, it has also been the subject of significant scrutiny regarding its clinical effectiveness.
Next, Check Out
Report from the Field: Lessons from Watchman Device Early Adopters